Tardive Dyskinesia in Older Persons Taking Antipsychotics

References

• Rao AS, Camilleri M. Review article: metoclopramide and tardive dyskinesia. Aliment Pharmacol Ther. 2010;31(1):11–19. doi:10.1111/j.1365-2036.2009.04189.x19886950
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed. Arlingtion, VA: American Psychiatric Association; 2013.
   Google Scholar
• McEvoy J, Gandhi SK, Rizio AA, et al. Effect of tardive dyskinesia on quality of life in patients with bipolar disorder, major depressive disorder, and schizophrenia. Qual Life Res. 2019;28(12):3303–3312. doi:10.1007/s11136-019-02269-831435866
   PubMed Web of Science ®Google Scholar
• Cornett EM, Novitch M, Kaye AD, Kata V, Kaye AM. Medication-induced tardive dyskinesia: a review and update. Ochsner J. 2017;17(2):162–174.28638290
   PubMed Web of Science ®Google Scholar
• Woods SW, Morgenstern H, Saksa JR, et al. Incidence of tardive dyskinesia with atypical versus conventional antipsychotic medications: a prospective cohort study. J Clin Psychiatry. 2010;71(4):463–474. doi:10.4088/JCP.07m03890yel20156410
   PubMed Web of Science ®Google Scholar
• Correll CU, Leucht S, Kane JM. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. Am J Psychiatry. 2004;161(3):414–425. doi:10.1176/appi.ajp.161.3.41414992963
   PubMed Web of Science ®Google Scholar
• Jeste DV. Tardive dyskinesia in older patients. J Clin Psychiatry. 2000;61(Suppl 4):27–32.
   PubMed Web of Science ®Google Scholar
• Carton L, Cottencin O, Lapeyre-Mestre M, et al. Off-label prescribing of antipsychotics in adults, children and elderly individuals: a systematic review of recent prescription trends. Curr Pharm Des. 2015;21(23):3280–3297. doi:10.2174/138161282166615061909290326088115
   PubMed Web of Science ®Google Scholar
• Citrome L, Kalsekar I, Guo Z, Laubmeier K, Hebden T. Diagnoses associated with use of atypical antipsychotics in a commercial health plan: a claims database analysis. Clin Ther. 2013;35(12):1867–1875. doi:10.1016/j.clinthera.2013.09.00624119767
   PubMed Web of Science ®Google Scholar
• Alexander GC, Gallagher SA, Mascola A, Moloney RM, Stafford RS. Increasing off-label use of antipsychotic medications in the United States, 1995–2008. Pharmacoepidemiol Drug Saf. 2011;20(2):177–184. doi:10.1002/pds.208221254289
   PubMed Web of Science ®Google Scholar
• Steinberg M, Lyketsos CG. Atypical antipsychotic use in patients with dementia: managing safety concerns. Am J Psychiatry. 2012;169(9):900–906. doi:10.1176/appi.ajp.2012.1203034222952071
   PubMed Web of Science ®Google Scholar
• Caroff SN, Leong SH, Roberts C, Berkowitz RM, Campbell EC. Cumulative burden of illness in veterans with tardive dyskinesia and serious mental disorders. J Clin Psychopharmacol. 2020;40(1):38–45. doi:10.1097/JCP.000000000000114231834084
   PubMed Web of Science ®Google Scholar
• Patel RS, Mansuri Z, Chopra A. Analysis of risk factors and outcomes in psychiatric inpatients with tardive dyskinesia: a nationwide case-control study. Heliyon. 2019;5(5):e01745. doi:10.1016/j.heliyon.2019.e0174531193370
   PubMed Web of Science ®Google Scholar
• Waln O, Jankovic J. An update on tardive dyskinesia: from phenomenology to treatment. Tremor Other Hyperkinet Mov (N Y). 2013;3. doi:10.7916/D88P5Z71
   PubMedGoogle Scholar
• Loughlin AM, Lin N, Abler V, Carroll B. Tardive dyskinesia among patients using antipsychotic medications in customary clinical care in the United States. PLoS One. 2019;14(6):e0216044. doi:10.1371/journal.pone.021604431163035
   PubMed Web of Science ®Google Scholar
• Jeste DV. Tardive dyskinesia rates with atypical antipsychotics in older adults. J Clin Psychiatry. 2004;65(Suppl 9):21–24.
   PubMed Web of Science ®Google Scholar
• Jain R, Correll CU. Tardive dyskinesia: recognition, patient assessment, and differential diagnosis. J Clin Psychiatry. 2018;79(2):16–23. doi:10.4088/JCP.nu17034ah1c
   Web of Science ®Google Scholar
• Divac N, Prostran M, Jakovcevski I, Cerovac N. Second-generation antipsychotics and extrapyramidal adverse effects. Biomed Res Int. 2014;2014:656370. doi:10.1155/2014/65637024995318
   PubMed Web of Science ®Google Scholar
• Pandey S. Orofacial dyskinesia in elderly. Mov Disord Clin Pract. 2015;2(4):442. doi:10.1002/mdc3.1219230838247
   PubMedGoogle Scholar
• Kuo SH, Jankovic J. Tardive gait. Clin Neurol Neurosurg. 2008;110(2):198–201. doi:10.1016/j.clineuro.2007.09.01317997030
   PubMed Web of Science ®Google Scholar
• Caroff SN, Yeomans K, Lenderking WR, et al. RE-KINECT: a prospective study of the presence and healthcare burden of tardive dyskinesia in clinical practice settings. J Clin Psychopharmacol. 2020;40(3):259–268. doi:10.1097/JCP.000000000000120132332461
   PubMed Web of Science ®Google Scholar
• Carroll B, Irwin DE. Health care resource utilization and costs for patients with tardive dyskinesia. J Manag Care Spec Pharm. 2019;25(7):810–816.31232207
   PubMed Web of Science ®Google Scholar
• Ward KM, Citrome L. Antipsychotic-related movement disorders: drug-induced parkinsonism vs. tardive dyskinesia-key differences in pathophysiology and clinical management. Neurol Ther. 2018;7(2):233–248. doi:10.1007/s40120-018-0105-030027457
   PubMed Web of Science ®Google Scholar
• Chong SA, Mahendran R, Machin D, Chua HC, Parker G, Kane J. Tardive dyskinesia among Chinese and Malay patients with schizophrenia. J Clin Psychopharmacol. 2002;22(1):26–30. doi:10.1097/00004714-200202000-0000511799339
   PubMed Web of Science ®Google Scholar
• Caroff SN, Ungvari GS, Cunningham Owens DG. Historical perspectives on tardive dyskinesia. J Neurol Sci. 2018;389:4–9. doi:10.1016/j.jns.2018.02.01529454494
   PubMed Web of Science ®Google Scholar
• Yassa R, Jones BD. Complications of tardive dyskinesia: a review. Psychosomatics. 1985;26(4):305–307, 310, 312–313. doi:10.1016/S0033-3182(85)72863-0
   Web of Science ®Google Scholar
• Kane JM, Smith JM. Tardive dyskinesia: prevalence and risk factors, 1959 to 1979. Arch Gen Psychiatry. 1982;39(4):473–481. doi:10.1001/archpsyc.1982.042900400690106121548
   PubMed Web of Science ®Google Scholar
• Carbon M, Hsieh CH, Kane JM, Correll CU. Tardive dyskinesia prevalence in the period of second-generation antipsychotic use: a meta-analysis. J Clin Psychiatry. 2017;78(3):e264–e278. doi:10.4088/JCP.16r1083228146614
   PubMed Web of Science ®Google Scholar
• Correll CU, Schenk EM. Tardive dyskinesia and new antipsychotics. Curr Opin Psychiatry. 2008;21(2):151–156. doi:10.1097/YCO.0b013e3282f5313218332662
   PubMed Web of Science ®Google Scholar
• Solmi M, Pigato G, Kane JM, Correll CU. Treatment of tardive dyskinesia with VMAT-2 inhibitors: a systematic review and meta-analysis of randomized controlled trials. Drug Des Devel Ther. 2018;12:1215–1238. doi:10.2147/DDDT.S133205
   PubMed Web of Science ®Google Scholar
• Patterson-Lomba O, Ayyagari R, Carroll B. Risk assessment and prediction of TD incidence in psychiatric patients taking concomitant antipsychotics: a retrospective data analysis. BMC Neurol. 2019;19(1):174. doi:10.1186/s12883-019-1385-431325958
   PubMed Web of Science ®Google Scholar
• Tenback DE, Bakker PR, van Harten PN. [Risk factors for tardive movement disorders in schizophrenia]. Tijdschr Psychiatr. 2015;57(2):120–124. Dutch.25669950
   PubMedGoogle Scholar
• Solmi M, Pigato G, Kane JM, Correll CU. Clinical risk factors for the development of tardive dyskinesia. J Neurol Sci. 2018;389:21–27. doi:10.1016/j.jns.2018.02.01229439776
   PubMed Web of Science ®Google Scholar
• Vardar MK, Ceylan ME, Unsalver BO. Assessment of risk factors for tardive dyskinesia. Psychopharmacol Bull. 2020;50(3):36–46.
   Google Scholar
• Woerner MG, Alvir JM, Saltz BL, Lieberman JA, Kane JM. Prospective study of tardive dyskinesia in the elderly: rates and risk factors. Am J Psychiatry. 1998;155(11):1521–1528. doi:10.1176/ajp.155.11.15219812112
   PubMed Web of Science ®Google Scholar
• Woerner MG, Correll CU, Alvir JM, Greenwald B, Delman H, Kane JM. Incidence of tardive dyskinesia with risperidone or olanzapine in the elderly: results from a 2-year, prospective study in antipsychotic-naive patients. Neuropsychopharmacology. 2011;36(8):1738–1746. doi:10.1038/npp.2011.5521508932
   PubMed Web of Science ®Google Scholar
• Jeste DV, Okamoto A, Napolitano J, Kane JM, Martinez RA. Low incidence of persistent tardive dyskinesia in elderly patients with dementia treated with risperidone. Am J Psychiatry. 2000;157(7):1150–1155. doi:10.1176/appi.ajp.157.7.115010873925
   PubMed Web of Science ®Google Scholar
• Vieta E, Goikolea JM, Corbella B, et al. Risperidone safety and efficacy in the treatment of bipolar and schizoaffective disorders: results from a 6-month, multicenter, open study. J Clin Psychiatry. 2001;62(10):818–825. doi:10.4088/JCP.v62n101111816872
   PubMed Web of Science ®Google Scholar
• Purdon SE, Jones BD, Stip E, et al. Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. The Canadian Collaborative Group for research in schizophrenia. Arch Gen Psychiatry. 2000;57(3):249–258. doi:10.1001/archpsyc.57.3.24910711911
   PubMed Web of Science ®Google Scholar
• Estevez-Fraga C, Zeun P, Lopez-Sendon Moreno JL. Current methods for the treatment and prevention of drug-induced parkinsonism and tardive dyskinesia in the elderly. Drugs Aging. 2018;35(11):959–971. doi:10.1007/s40266-018-0590-y30357723
   PubMed Web of Science ®Google Scholar
• Crystal S, Olfson M, Huang C, Pincus H, Gerhard T. Broadened use of atypical antipsychotics: safety, effectiveness, and policy challenges. Health Aff (Millwood). 2009;28(5):w770–w781. doi:10.1377/hlthaff.28.5.w77019622537
   PubMed Web of Science ®Google Scholar
• Kamble P, Sherer J, Chen H, Aparasu R. Off-label use of second-generation antipsychotic agents among elderly nursing home residents. Psychiatr Serv. 2010;61(2):130–136. doi:10.1176/ps.2010.61.2.13020123817
   PubMed Web of Science ®Google Scholar
• Maust DT, Kim HM, Chiang C, Kales HC. Association of the Centers for Medicare & Medicaid Services’ National Partnership to Improve Dementia Care with the use of antipsychotics and other psychotropics in long-term care in the United States from 2009 to 2014. JAMA Intern Med. 2018;178(5):640–647. doi:10.1001/jamainternmed.2018.037929550856
   PubMed Web of Science ®Google Scholar
• Maust DT, Strominger J, Bynum JPW, et al. Prevalence of psychotropic and opioid prescription fills among community-dwelling older adults with dementia in the US. JAMA. 2020;324(7):706–708. doi:10.1001/jama.2020.851932808997
   PubMed Web of Science ®Google Scholar
• Centers for Medicare and Medicaid Services. Atypical antipsychotic medications: use in adults [fact sheet]. Services UDoHaH, ed. US Department of Health and Human Services; 2015. Available from: https://www.cms.gov/Medicare-Medicaid-Coordination/Fraud-Prevention/Medicaid-Integrity-Education/Pharmacy-Education-Materials/Downloads/atyp-antipsych-adult-factsheet11-14.pdf. Accessed September 24, 2021.
   Google Scholar
• Yassa R, Lal S. Respiratory irregularity and tardive dyskinesia. A prevalence study. Acta Psychiatr Scand. 1986;73(5):506–510. doi:10.1111/j.1600-0447.1986.tb02717.x2875609
   PubMed Web of Science ®Google Scholar
• Blanchet PJ, Popovici R, Guitard F, Rompre PH, Lamarche C, Lavigne GJ. Pain and denture condition in edentulous orodyskinesia: comparisons with tardive dyskinesia and control subjects. Mov Disord. 2008;23(13):1837–1842. doi:10.1002/mds.2210218759358
   PubMed Web of Science ®Google Scholar
• Godlee FN, Brooks DJ, Impallomeni M. Dyskinesia in the elderly presenting as respiratory disorder. Postgrad Med J. 1989;65(769):830–831. doi:10.1136/pgmj.65.769.8302616417
   PubMed Web of Science ®Google Scholar
• Klawans HL Jr, Rubovits R. An experimental model of tardive dyskinesia. J Neural Transm. 1972;33(3):235–246. doi:10.1007/BF012453204674512
   PubMed Web of Science ®Google Scholar
• Tarsy D, Baldessarini RJ. Pharmacologically induced behavioural supersensitivity to apomorphine. Nat New Biol. 1973;245(148):262–263. doi:10.1038/newbio245262a04518989
   PubMedGoogle Scholar
• Stegmayer K, Walther S, van Harten P. Tardive dyskinesia associated with atypical antipsychotics: prevalence, mechanisms and management strategies. CNS Drugs. 2018;32(2):135–147. doi:10.1007/s40263-018-0494-829427000
   PubMed Web of Science ®Google Scholar
• Stahl SM. Neuronal traffic signals in tardive dyskinesia: not enough “stop” in the motor striatum. CNS Spectr. 2017;22(6):427–434. doi:10.1017/S109285291700061X29205123
   PubMed Web of Science ®Google Scholar
• Fedorenko OY, Loonen AJ, Lang F, et al. Association study indicates a protective role of phosphatidylinositol-4-phosphate-5-kinase against tardive dyskinesia. Int J Neuropsychopharmacol. 2015;18(6):pyu098. doi:10.1093/ijnp/pyu098
   Web of Science ®Google Scholar
• Basile VS, Masellis M, Badri F, et al. Association of the MscI polymorphism of the dopamine D3 receptor gene with tardive dyskinesia in schizophrenia. Neuropsychopharmacology. 1999;21(1):17–27. doi:10.1016/S0893-133X(98)00114-610379516
   PubMed Web of Science ®Google Scholar
• MacNeil RR, Muller DJ. Genetics of common antipsychotic-induced adverse effects. Mol Neuropsychiatry. 2016;2(2):61–78. doi:10.1159/00044580227606321
   PubMedGoogle Scholar
• Meltzer HY. The role of serotonin in antipsychotic drug action. Neuropsychopharmacology. 1999;21(2 Suppl):106s–115s. doi:10.1016/S0893-133X(99)00046-910432496
   PubMed Web of Science ®Google Scholar
• Kapur S, Seeman P. Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: A new hypothesis. Am J Psychiatry. 2001;158(3):360–369. doi:10.1176/appi.ajp.158.3.36011229973
   PubMed Web of Science ®Google Scholar
• Yu T, Li Y, Fan F, et al. Decreased gray matter volume of cuneus and lingual gyrus in schizophrenia patients with tardive dyskinesia is associated with abnormal involuntary movement. Sci Rep. 2018;8(1):12884. doi:10.1038/s41598-018-31186-y30150749
   PubMed Web of Science ®Google Scholar
• Yu T, Li Y, Li N, et al. Abnormal functional connectivity of motor circuit in the schizophrenic patients with tardive dyskinesia: a resting-state fMRI study. Neurosci Lett. 2021;742:135548. doi:10.1016/j.neulet.2020.13554833279570
   PubMed Web of Science ®Google Scholar
• Caroff SN. Overcoming barriers to effective management of tardive dyskinesia. Neuropsychiatr Dis Treat. 2019;15:785–794. doi:10.2147/NDT.S19654131040678
   PubMed Web of Science ®Google Scholar
• Salem H, Pigott T, Zhang XY, Zeni CP, Teixeira AL. Antipsychotic-induced Tardive dyskinesia: from biological basis to clinical management. Expert Rev Neurother. 2017;17(9):883–894. doi:10.1080/14737175.2017.136132228750568
   PubMed Web of Science ®Google Scholar
• Street JS, Clark WS, Gannon KS, et al. Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: a double-blind, randomized, placebo-controlled trial. The HGEU Study Group. Arch Gen Psychiatry. 2000;57(10):968–976. doi:10.1001/archpsyc.57.10.96811015815
   PubMed Web of Science ®Google Scholar
• Davis J, Zamora D, Horowitz M, Leucht S. Evaluating pimavanserin as a treatment for psychiatric disorders: A pharmacological property in search of an indication. Expert Opin Pharmacother. 2021;22(13):1651–1660. doi:10.1080/14656566.2021.1942455
   Google Scholar
• Koblan KS, Kent J, Hopkins SC, et al. A non-D2-receptor-binding drug for the treatment of schizophrenia. N Engl J Med. 2020;382(16):1497–1506. doi:10.1056/NEJMoa1911772
   Google Scholar
• Dean B, Scarr E. Muscarinic M1 and M4 receptors: hypothesis driven drug development for schizophrenia. Psychiatry Res. 2020;288:112989. doi:10.1016/j.psychres.2020.11298932315882
   PubMed Web of Science ®Google Scholar
• Brannan SK, Sawchak S, Miller AC, Lieberman JA, Paul SM, Breier A. Muscarinic cholinergic receptor agonist and peripheral antagonist for schizophrenia. N Engl J Med. 2021;384(8):717–726. doi:10.1056/NEJMoa201701533626254
   PubMed Web of Science ®Google Scholar
• Citrome L. Clinical management of tardive dyskinesia: five steps to success. J Neurol Sci. 2017;383:199–204. doi:10.1016/j.jns.2017.11.01929246613
   PubMed Web of Science ®Google Scholar
• Ricciardi L, Pringsheim T, Barnes TRE, et al. Treatment recommendations for tardive dyskinesia. Can J Psychiatry. 2019;64(6):388–399. doi:10.1177/070674371982896830791698
   PubMed Web of Science ®Google Scholar
• Bergman H, Rathbone J, Agarwal V, Soares‐Weiser K. Antipsychotic reduction and/or cessation and antipsychotics as specific treatments for tardive dyskinesia. Cochrane Database Syst Rev. 2018;2018(2):CD000459.
   Google Scholar
• Fernandez HH, Stamler D, Davis MD, et al. Long-term safety and efficacy of deutetrabenazine for the treatment of tardive dyskinesia. J Neurol Neurosurg Psychiatry. 2019;90(12):1317–1323.31296586
   PubMedGoogle Scholar
• Niemann N, Jankovic J. Treatment of tardive dyskinesia: a general overview with focus on the vesicular monoamine transporter 2 inhibitors. Drugs. 2018;78(5):525–541. doi:10.1007/s40265-018-0874-x29484607
   PubMed Web of Science ®Google Scholar
• Keepers GA, Fochtmann LJ, Anzia JM, et al. The American psychiatric association practice guideline for the treatment of patients with schizophrenia. Am J Psychiatry. 2020;177(9):868–872. doi:10.1176/appi.ajp.2020.17790132867516
   PubMed Web of Science ®Google Scholar
• Sajatovic M, Alexopoulos G, Burke J, Farahmand K, Siegert S. The effects of valbenazine on tardive dyskinesia in older and younger patients. Int J Geriatr Psychiatry. 2020;35:69–79. doi:10.1002/gps.521831617235
   PubMed Web of Science ®Google Scholar
• Sajatovic M, Wilhelm A, Finkbeiner S, et al. Long-term safety and efficacy of deutetrabenazine in younger and older patients with tardive dyskinesia. CNS Spectr. 2021;26(2):157–158. doi:10.1017/S1092852920002527
   Google Scholar
• Touma KTB, Scarff JR. Valbenazine and deutetrabenazine for tardive dyskinesia. Innov Clin Neurosci. 2018;15(5–6):13–16.
   PubMedGoogle Scholar
• Lerner PP, Miodownik C, Lerner V. Tardive dyskinesia (syndrome): current concept and modern approaches to its management. Psychiatry Clin Neurosci. 2015;69(6):321–334. doi:10.1111/pcn.1227025556809
   PubMed Web of Science ®Google Scholar
• Lupu AM, MacCamy KL, Gannon JM, Brar JS, Chengappa KNR. Less is more: deprescribing anticholinergic medications in persons with severe mental illness. Ann Clin Psychiatry. 2021;33(2):80–92.33878282
   PubMedGoogle Scholar
• McEvoy J, Park T, Schilling T, Terasawa E, Ayyagari R, Carroll B. The burden of tardive dyskinesia secondary to antipsychotic medication use among patients with mental disorders. Curr Med Res Opin. 2019;35(7):1205–1214. doi:10.1080/03007995.2019.156987130638073
   PubMed Web of Science ®Google Scholar